# An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/over-the-counter-cannabidiol-products-uk-quality-analysis/ > **Published:** 2022-02-08T15:53:24-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:46-04:00 > **Clinical Summary:** Explore the quality and composition of over-the-counter cannabidiol products UK, highlighting CBD content and presence of illegal substances. --- Cannabidiol (CBD), one of the major constituents of the plant cannabis, has received increasing interest in the United Kingdom in recent years for valid reasons. Research has proven its broad range of therapeutic properties including anti-inflammatory, anticonvulsant, pain-relieving and anxiety-relieving among others, as well as its favorable safety and tolerability profile. Currently, CBD-containing medicinal products are in [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) for the treatment of various diseases, and Epidiolex – a pure plant-derived CBD – has been approved to be a therapy for two seizure disorders. However, not everyone can acquire CBD safely from medical providers. Since it is not a controlled substance in the UK, CBD-based products are widely commercially available and increasingly popular, primarily in an oil format. A study into 29 most popular items in the UK from 27 brands has uncovered many issues in compositions of over-the-counter [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). First, the mean advertised CBD content is 4.5%, while the actual mean measured CBD content of products is significantly lower at 3.2%. Only 11/29 (38%) products have within 10% of the advertised CBD concentration. Second, 16/29 (55%) contain measurable levels of delta-tetrahydrocannabinol (THC) (with a mean content of 0.04%) or cannabinol (CBN) (with a mean content of 0.01%), as well as most other phytocannabinoid compounds including cannabidiolic acid (CBDA), cannabidivarin (CBDV), and cannabidivarin acid (CBDVA). It is important to note that THC and CBN are psychoactive components of cannabis and thus are classified as [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/), rendering products containing them illegal to possess. Altogether, these findings are warnings that the quality of many over-the-counter CBD-based products in the UK are substandard, especially with regards to CBD content and levels of illegal substances. [More access here](https://cedclinic.com/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Many Hemp Intoxicants Contain THC, Synthetic Cannabinoids – NORML](https://cedclinic.com/unregulated-intoxicating-hemp-products-risks-safety/) This article discusses the presence of THC and synthetic cannabinoids in [hemp products](https://cedclinic.com/texas-hemp-stricter-thc-rules-march-31-2026/), highlighting regulatory and safety concerns. [Read More](https://cedclinic.com/unregulated-intoxicating-hemp-products-risks-safety/) [Cannabidiol usage is correlated with marker of liver damage in healthy adults](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) Explore research linking cannabidiol usage with [liver health](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) markers in adults, emphasizing the importance of product quality. [Learn More](https://cedclinic.com/cannabidiol-liver-enzyme-elevation-healthy-adults/) [The wide distribution of cannabinoid receptors in the gastrointestinal tract suggests cannabinoids like CBD can relieve GI pain](https://cedclinic.com/cannabinoid-receptors-gastrointestinal-tract/) This article reviews the potential of cannabinoids such as CBD to alleviate gastrointestinal pain through receptor interactions. [Discover More](https://cedclinic.com/cannabinoid-receptors-gastrointestinal-tract/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=An%20Analysis%20of%20Over-the-Counter%20Cannabidiol%20Products%20in%20the%20United%20Kingdom&url=https%3A%2F%2Fcedclinic.com%2Fover-the-counter-cannabidiol-products-uk-quality-analysis%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fover-the-counter-cannabidiol-products-uk-quality-analysis%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=An%20Analysis%20of%20Over-the-Counter%20Cannabidiol%20Products%20in%20the%20United%20Kingdom%20https%3A%2F%2Fcedclinic.com%2Fover-the-counter-cannabidiol-products-uk-quality-analysis%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).